52 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
investments, that, paired with our enhanced deal skillset and expanded team, are expected to add robust programs and diversity to our product pipeline … in FSGS; the timing of clinical and regulatory events of Ligand’s partners; the expansion and diversity of Ligand’s portfolio; and guidance regarding
425
EX-99.1
ed3089ibsuxq 504b8
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
99z3xomts
21 Jun 22
Regulation FD Disclosure
6:19am
425
EX-99.3
8rgvgoiid1eh01m1lt7
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.2
mmgi3 ek39sb76jrnmc
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
ap5emsllraex9tpg
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.2
4lquupqwep6v2bz1ly
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
f5vokjfc wfvcx1mrlbz
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
eyc0qw0qjl
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
DEFA14A
k9pekin6s1lkhe
4 Jun 19
Additional proxy soliciting materials
5:07pm